M.BENI G2A009088 Bab8KTI
1
DAFTAR PUSTAKA
1. Indonesia Society of Intensive Care Unit. [cited 2012 Sept 23]. Available
from
http://www.perdici.org/
2. Dewoto, H.R, et al. Buku Farmakologi dan Terapi edisi 5 : Antikoagulan,
Antitrombotik, Trombolitik dan Hemostatik. Jakarta: Departemen
Farmakologi dan Terapeutik FKUI, 2009: 804-810
3. Adi Satrio. Pengaruh pemberian heparin subkutan dan heparin intravena
sebagai profilaksis thrombosis vena dalam (TVD) terhadap PTT/K dan
jumlah trombosit pada pasien di ICU RSUP DR. Kariadi Semarang. 2013.
[cited 2013 February 28]. Available from eprints.undip.ac.id/
4. Sam Schulman. Hemorrhagic Complications of Anticoagulant and
Thrombolytic Treatment American College of Chest Physicians Evidence
Based Clinical Practice Guidelines (8th Edition). (CHEST 2008;
133:257S–298S).
[cited
2012
Sept
29].
Available
from
http://publications.chestnet.org
5. Maureen A Smythe. Use of the Activated Partial Thromboplastin Time for
Heparin Monitoring. (Am J Clin Pathol 2001;115:148-155). [cited 2013
February 28]. Available from http://ajcp.ascpjournals.org
6. Syed Reza. Assessment of Bleeding Risk in Patients on Antiplatelet and
Anticoagulant Therapy. 2012. [cited 2013 February 28]. Available from
http://www.priory.com/medicine/bleeding_risk.htm
7. Ridzky Djanuar. Perbandingan pemberian heparin intravena dan subkutan
terhadap kadar PPT dan PTTK pada pencegahan Deep Vein Thrombosis. .
2012. [cited 2013 Jun 28]. Available from eprints.undip.ac.id/
2
8. Riskiawan Angga. Pengaruh pemberian heparin intravena sebagai
profilaksis Deep Vein Thrombosis terhadap nilai PPT dan PTTK. 2012.
[cited 2013 Jun 28]. Available from eprints.undip.ac.id/
9. Jack Hirsh, Theodore E. Warkentin, et al. Heparin and Low-MolecularWeight Heparin Mechanisms of Action, Pharmacokinetics, Dosing,
Monitoring, Efficacy, and Safety (CHEST 2004; 126:188S–20). [cited
2012 Sept 28]. Available from http://publications.chestnet.org
10. Jack Hirsh, Kenneth A. Bauer, et al. Parenteral Anticoagulants. American
College of Chest Physicians Evidence-Based Clinical Practice Guidelines
(8th Edition) (CHEST 2008; 133:141S–159S). [cited 2012 Sept 28].
Available from http://publications.chestnet.org
11. Levitan N, Dowlati A, et al. Rates of initial and recurrent thromboembolic
disease among patients with malignancy versus those without malignancy.
Risk analysis using Medicare claims data. 1999 (Sep);78(5):285–91. [cited
2013 May 28]. Available from www.ncbi.nlm.nih.gov/pubmed/10499070
12. Goitom Hagos, M.D. Lower Extremity Deep Vein Thrombosis among
Intensive Care Patients in Orotta, National Referral Hospital, Asmara,
Eritrea, JEMA; 2008. ) [cited 2013 May 28]. Available from
www.ajol.info/index.php/jema/.../40736
13. Michael K Gould. LMWH compare with UHF for treatment of Deep
Acute Vein Thrombosis – A cost effectiveness analysis. (Ann Intern
Med.2001;130:789-799).
[cited
2012
Sept
26].
Available
from
http://publications.chestnet.org
14. Theodore E. Warkentin. Prevalence and Risk of Preexisting HeparinInduced Thrombocytopenia Antibodies in Patients With Acute VTE.
(CHEST 2011; 140(2):366–373). [cited 2012 Sept 30]. Available from
http://publications.chestnet.org
15. Gennari C, Martini G. Secondary osteoporosis. 10(3):214-24 1998 Jun.
Institut of Medical Pathology, University of Siena, Italy. [cited 2012 oct
3
1].
[cited
2012
Sept
28].
Available
from
http://www.ncbi.nlm.nih.gov/pubmed
16. M.R. Caballeroand M. Allergy to heparin: A new vitrodiagnostic
technique. Allergy and Immunopathology 2003;31(6):324-8. Departament
Allergy and Immunology, Faculty of Medicine, University de Navarra,
Pamplona. Spain. [cited 2012 Oct 1]. [cited 2012 Sept 28]. Available from
http://www.ncbi.nlm.nih.gov/pubmed
17. Ronald, Reagan. Anticoagulant Management Program and Guidelines.
UCLA Medical Center. 2008. [cited 2012 Sept 28]. Available from
http://medres.med.ucla.edu/guidelines
18. Peterson D, Harward S, Lawson J.H. Anticoagulation strategies for
venous thromboembolism. Perspect Vasc Surg Endovasc Ther 2009;
21;125.
)
[cited
2012
Sept
28].
Available
from
http://www.ncbi.nlm.nih.gov/pubmed
19. Suharti C. Dasar-DasarHemostasis.Dalam :Aru W Sundarudkk. (editor)
Buku Ajar Ilmu Penyakit Dalam.Edisi keempat.Jakarta. Pusat Penerbitan
Departemen Ilmu Penyakit Dalam. Edisi keempat. Jakarta. Pusat
Penerbitan Departemen Ilmu Penyakit Dalam FKUI.2006
20. Wijanda Hidajati S. Stabilitas sampel plasma sitrat selama penyimpanan
untuk pemeriksaan APTT dan PT. (Dept Patologi Klinik 2012).[cited 2013
February 28]. Available from http://penelitian.unair.ac.id/artikel_dosen
21. Kitchen S. Prothrombine time and INR. 2010. [cited 2013 Jun 28].
Available from http://pathology.vcu.edu/clinical/coag/PT%20INR.Pdf
22. Roger S. Riley. Activated Partial Thromboplastin Time (APTT). April
2005. [cited 2013 February 28]. Available from http://pathology.vcu.edu
23. Agnelli G, Caprini JA. The Prophylaxis of Venous Thrombosis in Patients
with Cancer Undergoing Major Abdominal Surgery: emerging options. J
Surg Oncol 2007;96:265-272. [cited 2013 February 28]. Available from
http://ncbi.nlm.nih.gov/pubmed/17474075
4
24. Gottfried EL and Adachi MM, "Prothrombin Time and Activated Partial
Thromboplastin Time Can Be Performed on the First Tube,"Am J Clin
Pathol, 1997, 107(6):681-3. [cited 2013 Jun 28]. Available from
http://ncbi.nlm.nih.gov/pubmed/9169665
25. Sukrisman L. Trombosis Vena Dalam dan Emboli Paru dalam Ilmu
Penyakit Dalam. Penerbit FKUI. Jakarta, 2006; 802-03
26. William H. Geerts. Prevention of Venous Thromboembolism. (CHEST
2008;
133:381S–453S).
[cited
http://publications.chestnet.org
2013
July
2].
Available
from
5
6
7
No
Register
Diagnosis
JK
Usia L.R BB Rute Jenis
1
2
3
4
5
6
7
8
9
10
11
C264762
C272181
C285953
C276475
C283471
C283444
C277275
C072726
C284326
C263161
C273627
Wanita
Laki-laki
Laki-laki
Wanita
Laki-laki
Wanita
Wanita
Wanita
Wanita
Laki-laki
Laki-laki
59
24
52
46
71
28
17
52
23
61
70
6
7
7
5
4
7
4
4
7
6
4
49
65
75
53
50
70
37
50
50
80
60
IV
IV
IV
IV
IV
IV
IV
IV
IV
IV
IV
UHF
UHF
UHF
UHF
UHF
UHF
UHF
UHF
UHF
UHF
UHF
12
13
14
15
16
17
18
C284590
C287341
C274874
C285394
C279894
C282255
C278454
Laki-laki
Laki-laki
Wanita
Wanita
Wanita
Laki-laki
Laki-laki
50
29
46
31
47
63
53
5
6
4
5
6
4
4
45
70
50
45
50
50
65
IV
IV
IV
IV
IV
IV
IV
UHF
UHF
UHF
UHF
UHF
UHF
UHF
19
C222772
Wanita
43
4
50
IV
UHF
20
21
22
23
C264314
C279975
C295047
C285953
Wanita
Laki-laki
Wanita
Laki-laki
41
44
18
52
7
4
4
7
40
65
45
50
IV
IV
IV
IV
UHF
UHF
UHF
UHF
24
25
26
27
28
29
30
C273019
C288064
C293794
C292436
C291327
C257977
B003309
Post CABG
Post OP DVR
Post Laparatomi
Post Histerektomi
Post Laparatomi
Post Laparatomi
Post OP DVR
Post Craniotomi
Post Laparatomi
Post OP URS
Post TPM
Post Fiksasi
Interna
Post Thoracotomi
Post Laparatomi
Post Craniotomi
Post Laparatomi
Post Thoracotomi
Post CABG
Post OP Kista
Ovarii
Post OP Tumor
Ovarii
Post Thoracotomi
Post Sectio
Post Laparatomi
Post
Oovaringektomi
Post Sectio
Post Histerektomi
Post Laparatomi
Post Laparatomi
Post CABG
Post EGD Biopsi
Wanita
Wanita
Wanita
Wanita
Wanita
Wanita
Laki-laki
50
35
15
70
48
44
68
7
7
5
5
6
7
7
65
45
50
65
50
70
50
IV
IV
IV
IV
IV
IV
IV
UHF
UHF
UHF
UHF
UHF
UHF
UHF
8
L.H Dosis
6
7
4
5
4
7
4
4
7
6
4
5
6
4
5
4
4
5
4
5
4
4
5
7
7
5
5
6
7
10
500
500
500
500
500
500
500
500
500
500
500
500
500
500
500
500
500
500
500
500
500
500
500
500
500
500
500
500
500
500
PTo
13.7
18.1
14.8
15.2
15.6
16.7
17.8
10.6
13.9
15.9
15.4
18.1
11.7
15.2
10.7
15.3
14.5
16.5
13
15.5
14.2
10
14.3
13.2
11.9
13.4
14.2
14.4
15.4
14.2
skor sebelum
skor sesudah
PTc APTTo APTTc PT1 PTc APTT1 APTTc
13.7
38.9
31.9 13.9 13.3
44.6
31.9
13.7
42
32.3
19 14.4
45.4
31.9
13.6
39.5
31.5 13.3 13.4
37.1
31.5
14.1
41.2
31.8 16.3
14
40.1
31.9
14.5
35.1
32.5 14.9 14.5
41.5
32.5
10.6
40.5
34.9 18.3 10.6
39
35
13.8
45.2
32.6 17.3 13.8
43.5
32.6
10.9
43.2
33.3 10.8 10.6
45.6
34.1
14.5
40.7
32.5 15.7 10.2
43.1
33.5
14.5
42.3
31.8
17 14.4
47.1
32
13.1
41.8
31.7 18.3 13.4
43.8
32.1
14.5
39.5
32.5 21.2 14.5
41.3
32.5
11.2
37.6
33.2
15 12.5
40.4
33.2
13.7
40.3
29
15 13.7
38.6
29
10.5
37.6
30.5 13.8 14.1
36.8
29.3
14.1
40.7
31.4 14.2 14.1
41.5
29.8
13.8
38.6
29.5 14.1 14.3
39.6
29.3
13.7
38.1
29 15.8 10.9
40.3
34.1
11.3
35.1
31.4
12
14
34.4
33.8
13.7
32.7
29 14.2 10.8
37.4
31.6
13.7
40.1
29
14 13.7
37.1
29
11.6
40.9
34.6
13 11.6
39.1
34.5
14.4
41.7
30.3 16.5 14.4
45.1
30.3
12.6
37.4
34
14 12.5
41.9
33.8
11
39.2
32 13.5 10.9
38.9
31.5
14.4
36
30.3 13.8 10.1
38.3
32
12.9
37.5
34
14
13
41
33.5
13.9
33.1
29.3 14.2 11.6
36.2
35
14
38.2
29.4
17 14.3
38.4
29.4
13.9
39.9
32.5 14.1 13.9
41.4
32.5
9
skor sebelum keluar ICU
PTx
PTc
APTTx APTTc
17.9
14.1
47.4
31.7
21.1
12.1
53
31.7
16.1
13.7
39.7
32.3
18.5
13.8
43.8
31.6
16.9
14.3
45.8
32.5
20.4
10.7
44.4
37.2
18
10.9
46.3
33.9
10.5
10.7
43.1
33.9
18
10.1
46.4
34.2
19.2
14.5
51
31.9
17.9
13.2
51.6
31.9
24.6
10.1
43
32.2
15.1
12.1
42
33.2
15.1
13.8
44
29.3
20.3
14.2
38.7
29.3
19
13.8
40.7
29.5
13.1
19.4
42
34.4
15.2
11
44.4
34
11.9
11
39.5
33.4
18.9
11.2
46.3
33.8
13.5
13.8
40.2
29
17.1
11.5
39
34.5
19
13.7
49.5
29.8
18.4
12.5
44
33.4
18
11.2
46
31.3
19.7
13.7
48.2
29.8
18.5
13.5
43.9
32.7
19.2
10.5
42.6
34.5
19.2
14
40.8
29.6
21.5
10.4
47.6
35.1
PTo
APTTo
PT1
APTT1
PTx
APTTx
PTc
PT sebelum mendapat heparin
APPT sebelum mendapat heparin
PT sesudah mendapat heparin
APTT sesudah mendapat heparin
PT sebelum keluar ICU
APTT sebelum keluar ICU
PT kontrol
10
Output SPSS
Descriptives
PT sebelum
menerima Heparin
APTT sebelum
menerima Heparin
Mean
95% Conf idence
Interv al f or Mean
5% Trimmed Mean
Median
Variance
Std. Dev iat ion
Minimum
Maximum
Range
Interquartile Range
Skewness
Kurt osis
Mean
95% Conf idence
Interv al f or Mean
5% Trimmed Mean
Median
Variance
Std. Dev iat ion
Minimum
Maximum
Range
Interquartile Range
Skewness
Kurt osis
Lower Bound
Upper Bound
Lower Bound
Upper Bound
Stat istic
14.4467
13.6744
Std. Error
.37758
15.2189
14.4796
14.4500
4.277
2.06810
10.00
18.10
8.10
2.18
-.322
.027
39.1533
38.0895
.427
.833
.52016
40.2172
39.2056
39.5000
8.117
2.84905
32.70
45.20
12.50
3.40
-.434
.301
.427
.833
11
Descriptives
PT setelah
menerima Heparin
APTT setelah
menerima Heparin
Mean
95% Conf idence
Interv al f or Mean
5% Trimmed Mean
Median
Variance
Std. Dev iat ion
Minimum
Maximum
Range
Interquartile Range
Skewness
Kurt osis
Mean
95% Conf idence
Interv al f or Mean
5% Trimmed Mean
Median
Variance
Std. Dev iat ion
Minimum
Maximum
Range
Interquartile Range
Skewness
Kurt osis
Lower Bound
Upper Bound
Lower Bound
Upper Bound
Stat istic
15.1400
14.3184
Std. Error
.40174
15.9616
15.0630
14.2000
4.842
2.20041
10.80
21.20
10.40
2.75
.768
.881
40.6167
39.4436
.427
.833
.57358
41.7898
40.5963
40.3500
9.870
3.14161
34.40
47.10
12.70
4.83
.223
-.564
.427
.833
12
Descriptives
PT sebelum
pasien keluar I CU
APTT sebelum
pasien keluar I CU
Mean
95% Conf idence
Interv al f or Mean
5% Trimmed Mean
Median
Variance
Std. Dev iat ion
Minimum
Maximum
Range
Interquart ile Range
Skewness
Kurt osis
Mean
95% Conf idence
Interv al f or Mean
5% Trimmed Mean
Median
Variance
Std. Dev iat ion
Minimum
Maximum
Range
Interquart ile Range
Skewness
Kurt osis
Lower Bound
Upper Bound
Lower Bound
Upper Bound
Stat istic
17.7267
16.6239
Std. Error
.53920
18.8294
17.7778
18.2000
8.722
2.95331
10.50
24.60
14.10
3.33
-.473
.843
44.4967
43.0826
.427
.833
.69140
45.9107
44.3667
44.0000
14.341
3.78695
38.70
53.00
14.30
4.95
.461
-.323
.427
.833
13
Tests of Normal ity
a
Kolmogorov -Smirnov
St at ist ic
df
Sig.
PT sebelum
menerima Heparin
APTT sebelum
menerima Heparin
PT set elah
menerima Heparin
APTT setelah
menerima Heparin
PT sebelum
pasien keluar ICU
APTT sebelum
pasien keluar ICU
St at ist ic
Shapiro-Wilk
df
Sig.
.119
30
.200*
.962
30
.352
.102
30
.200*
.974
30
.648
.199
30
.004
.939
30
.085
.089
30
.200*
.980
30
.822
.190
30
.007
.952
30
.190
.110
30
.200*
.965
30
.417
*. This is a lower bound of the true signif icance.
a. Lillief ors Signif icance Correction
Paired Samples Statistics
Mean
Pair
1
PT sebelum
menerima Heparin
PT setelah
menerima Heparin
N
Std. Dev iat ion
Std. Error
Mean
14.4467
30
2.06810
.37758
15.1400
30
2.20041
.40174
Paired Samples Test
Paired Dif f erences
Mean
Pair
1
PT sebelum menerima
Heparin - PT setelah
menerima Heparin
-.69333
St d. Dev iation
St d. Error
Mean
1.44650
.26409
95% Conf idence
Interv al of the
Dif f erence
Lower
Upper
-1.23347
-.15320
t
-2.625
df
Sig. (2-tailed)
29
Paired Samples Statistics
Mean
Pair
1
PT setelah
menerima Heparin
PT sebelum
pasien keluar ICU
N
Std. Dev iat ion
Std. Error
Mean
15.1400
30
2.20041
.40174
17.7267
30
2.95331
.53920
.014
14
Paired Samples Test
Paired Dif f erences
Mean
Pair
1
PT setelah menerima
Heparin - PT sebelum
pasien keluar ICU
Std. Dev iat ion
Std. Error
Mean
2.30856
.42148
-2.58667
95% Conf idence
Interv al of the
Dif f erence
Lower
Upper
-3.44870
-1.72463
t
df
Sig. (2-tailed)
-6.137
29
.000
Paired Samples Statistics
Mean
Pair
1
APTT sebelum
menerima Heparin
APTT setelah
menerima Heparin
N
Std. Dev iat ion
Std. Error
Mean
39.1533
30
2.84905
.52016
40.6167
30
3.14161
.57358
Paired Samples Test
Paired Dif f erences
Mean
Pair
1
APTT sebelum menerima
Heparin - APTT setelah
menerima Heparin
-1.46333
Std. Dev iat ion
Std. Error
Mean
2.55079
.46571
95% Conf idence
Interv al of the
Dif f erence
Lower
Upper
-2.41581
-.51085
t
df
-3.142
Sig. (2-tailed)
29
.004
Paired Samples Statistics
Mean
Pair
1
APTT setelah
menerima Heparin
APTT sebelum
pasien keluar ICU
N
Std. Dev iat ion
Std. Error
Mean
40.6167
30
3.14161
.57358
44.4967
30
3.78695
.69140
Paired Samples Test
Paired Dif f erences
Mean
Pair
1
APTT setelah menerima
Heparin - APTT sebelum
pasien keluar I CU
-3.88000
Std. Dev iat ion
Std. Error
Mean
2.78622
.50869
95% Conf idence
Interv al of the
Dif f erence
Lower
Upper
-4.92039
-2.83961
t
-7.627
df
Sig. (2-tailed)
29
.000
15
Dokumentasi Penelitian
DAFTAR PUSTAKA
1. Indonesia Society of Intensive Care Unit. [cited 2012 Sept 23]. Available
from
http://www.perdici.org/
2. Dewoto, H.R, et al. Buku Farmakologi dan Terapi edisi 5 : Antikoagulan,
Antitrombotik, Trombolitik dan Hemostatik. Jakarta: Departemen
Farmakologi dan Terapeutik FKUI, 2009: 804-810
3. Adi Satrio. Pengaruh pemberian heparin subkutan dan heparin intravena
sebagai profilaksis thrombosis vena dalam (TVD) terhadap PTT/K dan
jumlah trombosit pada pasien di ICU RSUP DR. Kariadi Semarang. 2013.
[cited 2013 February 28]. Available from eprints.undip.ac.id/
4. Sam Schulman. Hemorrhagic Complications of Anticoagulant and
Thrombolytic Treatment American College of Chest Physicians Evidence
Based Clinical Practice Guidelines (8th Edition). (CHEST 2008;
133:257S–298S).
[cited
2012
Sept
29].
Available
from
http://publications.chestnet.org
5. Maureen A Smythe. Use of the Activated Partial Thromboplastin Time for
Heparin Monitoring. (Am J Clin Pathol 2001;115:148-155). [cited 2013
February 28]. Available from http://ajcp.ascpjournals.org
6. Syed Reza. Assessment of Bleeding Risk in Patients on Antiplatelet and
Anticoagulant Therapy. 2012. [cited 2013 February 28]. Available from
http://www.priory.com/medicine/bleeding_risk.htm
7. Ridzky Djanuar. Perbandingan pemberian heparin intravena dan subkutan
terhadap kadar PPT dan PTTK pada pencegahan Deep Vein Thrombosis. .
2012. [cited 2013 Jun 28]. Available from eprints.undip.ac.id/
2
8. Riskiawan Angga. Pengaruh pemberian heparin intravena sebagai
profilaksis Deep Vein Thrombosis terhadap nilai PPT dan PTTK. 2012.
[cited 2013 Jun 28]. Available from eprints.undip.ac.id/
9. Jack Hirsh, Theodore E. Warkentin, et al. Heparin and Low-MolecularWeight Heparin Mechanisms of Action, Pharmacokinetics, Dosing,
Monitoring, Efficacy, and Safety (CHEST 2004; 126:188S–20). [cited
2012 Sept 28]. Available from http://publications.chestnet.org
10. Jack Hirsh, Kenneth A. Bauer, et al. Parenteral Anticoagulants. American
College of Chest Physicians Evidence-Based Clinical Practice Guidelines
(8th Edition) (CHEST 2008; 133:141S–159S). [cited 2012 Sept 28].
Available from http://publications.chestnet.org
11. Levitan N, Dowlati A, et al. Rates of initial and recurrent thromboembolic
disease among patients with malignancy versus those without malignancy.
Risk analysis using Medicare claims data. 1999 (Sep);78(5):285–91. [cited
2013 May 28]. Available from www.ncbi.nlm.nih.gov/pubmed/10499070
12. Goitom Hagos, M.D. Lower Extremity Deep Vein Thrombosis among
Intensive Care Patients in Orotta, National Referral Hospital, Asmara,
Eritrea, JEMA; 2008. ) [cited 2013 May 28]. Available from
www.ajol.info/index.php/jema/.../40736
13. Michael K Gould. LMWH compare with UHF for treatment of Deep
Acute Vein Thrombosis – A cost effectiveness analysis. (Ann Intern
Med.2001;130:789-799).
[cited
2012
Sept
26].
Available
from
http://publications.chestnet.org
14. Theodore E. Warkentin. Prevalence and Risk of Preexisting HeparinInduced Thrombocytopenia Antibodies in Patients With Acute VTE.
(CHEST 2011; 140(2):366–373). [cited 2012 Sept 30]. Available from
http://publications.chestnet.org
15. Gennari C, Martini G. Secondary osteoporosis. 10(3):214-24 1998 Jun.
Institut of Medical Pathology, University of Siena, Italy. [cited 2012 oct
3
1].
[cited
2012
Sept
28].
Available
from
http://www.ncbi.nlm.nih.gov/pubmed
16. M.R. Caballeroand M. Allergy to heparin: A new vitrodiagnostic
technique. Allergy and Immunopathology 2003;31(6):324-8. Departament
Allergy and Immunology, Faculty of Medicine, University de Navarra,
Pamplona. Spain. [cited 2012 Oct 1]. [cited 2012 Sept 28]. Available from
http://www.ncbi.nlm.nih.gov/pubmed
17. Ronald, Reagan. Anticoagulant Management Program and Guidelines.
UCLA Medical Center. 2008. [cited 2012 Sept 28]. Available from
http://medres.med.ucla.edu/guidelines
18. Peterson D, Harward S, Lawson J.H. Anticoagulation strategies for
venous thromboembolism. Perspect Vasc Surg Endovasc Ther 2009;
21;125.
)
[cited
2012
Sept
28].
Available
from
http://www.ncbi.nlm.nih.gov/pubmed
19. Suharti C. Dasar-DasarHemostasis.Dalam :Aru W Sundarudkk. (editor)
Buku Ajar Ilmu Penyakit Dalam.Edisi keempat.Jakarta. Pusat Penerbitan
Departemen Ilmu Penyakit Dalam. Edisi keempat. Jakarta. Pusat
Penerbitan Departemen Ilmu Penyakit Dalam FKUI.2006
20. Wijanda Hidajati S. Stabilitas sampel plasma sitrat selama penyimpanan
untuk pemeriksaan APTT dan PT. (Dept Patologi Klinik 2012).[cited 2013
February 28]. Available from http://penelitian.unair.ac.id/artikel_dosen
21. Kitchen S. Prothrombine time and INR. 2010. [cited 2013 Jun 28].
Available from http://pathology.vcu.edu/clinical/coag/PT%20INR.Pdf
22. Roger S. Riley. Activated Partial Thromboplastin Time (APTT). April
2005. [cited 2013 February 28]. Available from http://pathology.vcu.edu
23. Agnelli G, Caprini JA. The Prophylaxis of Venous Thrombosis in Patients
with Cancer Undergoing Major Abdominal Surgery: emerging options. J
Surg Oncol 2007;96:265-272. [cited 2013 February 28]. Available from
http://ncbi.nlm.nih.gov/pubmed/17474075
4
24. Gottfried EL and Adachi MM, "Prothrombin Time and Activated Partial
Thromboplastin Time Can Be Performed on the First Tube,"Am J Clin
Pathol, 1997, 107(6):681-3. [cited 2013 Jun 28]. Available from
http://ncbi.nlm.nih.gov/pubmed/9169665
25. Sukrisman L. Trombosis Vena Dalam dan Emboli Paru dalam Ilmu
Penyakit Dalam. Penerbit FKUI. Jakarta, 2006; 802-03
26. William H. Geerts. Prevention of Venous Thromboembolism. (CHEST
2008;
133:381S–453S).
[cited
http://publications.chestnet.org
2013
July
2].
Available
from
5
6
7
No
Register
Diagnosis
JK
Usia L.R BB Rute Jenis
1
2
3
4
5
6
7
8
9
10
11
C264762
C272181
C285953
C276475
C283471
C283444
C277275
C072726
C284326
C263161
C273627
Wanita
Laki-laki
Laki-laki
Wanita
Laki-laki
Wanita
Wanita
Wanita
Wanita
Laki-laki
Laki-laki
59
24
52
46
71
28
17
52
23
61
70
6
7
7
5
4
7
4
4
7
6
4
49
65
75
53
50
70
37
50
50
80
60
IV
IV
IV
IV
IV
IV
IV
IV
IV
IV
IV
UHF
UHF
UHF
UHF
UHF
UHF
UHF
UHF
UHF
UHF
UHF
12
13
14
15
16
17
18
C284590
C287341
C274874
C285394
C279894
C282255
C278454
Laki-laki
Laki-laki
Wanita
Wanita
Wanita
Laki-laki
Laki-laki
50
29
46
31
47
63
53
5
6
4
5
6
4
4
45
70
50
45
50
50
65
IV
IV
IV
IV
IV
IV
IV
UHF
UHF
UHF
UHF
UHF
UHF
UHF
19
C222772
Wanita
43
4
50
IV
UHF
20
21
22
23
C264314
C279975
C295047
C285953
Wanita
Laki-laki
Wanita
Laki-laki
41
44
18
52
7
4
4
7
40
65
45
50
IV
IV
IV
IV
UHF
UHF
UHF
UHF
24
25
26
27
28
29
30
C273019
C288064
C293794
C292436
C291327
C257977
B003309
Post CABG
Post OP DVR
Post Laparatomi
Post Histerektomi
Post Laparatomi
Post Laparatomi
Post OP DVR
Post Craniotomi
Post Laparatomi
Post OP URS
Post TPM
Post Fiksasi
Interna
Post Thoracotomi
Post Laparatomi
Post Craniotomi
Post Laparatomi
Post Thoracotomi
Post CABG
Post OP Kista
Ovarii
Post OP Tumor
Ovarii
Post Thoracotomi
Post Sectio
Post Laparatomi
Post
Oovaringektomi
Post Sectio
Post Histerektomi
Post Laparatomi
Post Laparatomi
Post CABG
Post EGD Biopsi
Wanita
Wanita
Wanita
Wanita
Wanita
Wanita
Laki-laki
50
35
15
70
48
44
68
7
7
5
5
6
7
7
65
45
50
65
50
70
50
IV
IV
IV
IV
IV
IV
IV
UHF
UHF
UHF
UHF
UHF
UHF
UHF
8
L.H Dosis
6
7
4
5
4
7
4
4
7
6
4
5
6
4
5
4
4
5
4
5
4
4
5
7
7
5
5
6
7
10
500
500
500
500
500
500
500
500
500
500
500
500
500
500
500
500
500
500
500
500
500
500
500
500
500
500
500
500
500
500
PTo
13.7
18.1
14.8
15.2
15.6
16.7
17.8
10.6
13.9
15.9
15.4
18.1
11.7
15.2
10.7
15.3
14.5
16.5
13
15.5
14.2
10
14.3
13.2
11.9
13.4
14.2
14.4
15.4
14.2
skor sebelum
skor sesudah
PTc APTTo APTTc PT1 PTc APTT1 APTTc
13.7
38.9
31.9 13.9 13.3
44.6
31.9
13.7
42
32.3
19 14.4
45.4
31.9
13.6
39.5
31.5 13.3 13.4
37.1
31.5
14.1
41.2
31.8 16.3
14
40.1
31.9
14.5
35.1
32.5 14.9 14.5
41.5
32.5
10.6
40.5
34.9 18.3 10.6
39
35
13.8
45.2
32.6 17.3 13.8
43.5
32.6
10.9
43.2
33.3 10.8 10.6
45.6
34.1
14.5
40.7
32.5 15.7 10.2
43.1
33.5
14.5
42.3
31.8
17 14.4
47.1
32
13.1
41.8
31.7 18.3 13.4
43.8
32.1
14.5
39.5
32.5 21.2 14.5
41.3
32.5
11.2
37.6
33.2
15 12.5
40.4
33.2
13.7
40.3
29
15 13.7
38.6
29
10.5
37.6
30.5 13.8 14.1
36.8
29.3
14.1
40.7
31.4 14.2 14.1
41.5
29.8
13.8
38.6
29.5 14.1 14.3
39.6
29.3
13.7
38.1
29 15.8 10.9
40.3
34.1
11.3
35.1
31.4
12
14
34.4
33.8
13.7
32.7
29 14.2 10.8
37.4
31.6
13.7
40.1
29
14 13.7
37.1
29
11.6
40.9
34.6
13 11.6
39.1
34.5
14.4
41.7
30.3 16.5 14.4
45.1
30.3
12.6
37.4
34
14 12.5
41.9
33.8
11
39.2
32 13.5 10.9
38.9
31.5
14.4
36
30.3 13.8 10.1
38.3
32
12.9
37.5
34
14
13
41
33.5
13.9
33.1
29.3 14.2 11.6
36.2
35
14
38.2
29.4
17 14.3
38.4
29.4
13.9
39.9
32.5 14.1 13.9
41.4
32.5
9
skor sebelum keluar ICU
PTx
PTc
APTTx APTTc
17.9
14.1
47.4
31.7
21.1
12.1
53
31.7
16.1
13.7
39.7
32.3
18.5
13.8
43.8
31.6
16.9
14.3
45.8
32.5
20.4
10.7
44.4
37.2
18
10.9
46.3
33.9
10.5
10.7
43.1
33.9
18
10.1
46.4
34.2
19.2
14.5
51
31.9
17.9
13.2
51.6
31.9
24.6
10.1
43
32.2
15.1
12.1
42
33.2
15.1
13.8
44
29.3
20.3
14.2
38.7
29.3
19
13.8
40.7
29.5
13.1
19.4
42
34.4
15.2
11
44.4
34
11.9
11
39.5
33.4
18.9
11.2
46.3
33.8
13.5
13.8
40.2
29
17.1
11.5
39
34.5
19
13.7
49.5
29.8
18.4
12.5
44
33.4
18
11.2
46
31.3
19.7
13.7
48.2
29.8
18.5
13.5
43.9
32.7
19.2
10.5
42.6
34.5
19.2
14
40.8
29.6
21.5
10.4
47.6
35.1
PTo
APTTo
PT1
APTT1
PTx
APTTx
PTc
PT sebelum mendapat heparin
APPT sebelum mendapat heparin
PT sesudah mendapat heparin
APTT sesudah mendapat heparin
PT sebelum keluar ICU
APTT sebelum keluar ICU
PT kontrol
10
Output SPSS
Descriptives
PT sebelum
menerima Heparin
APTT sebelum
menerima Heparin
Mean
95% Conf idence
Interv al f or Mean
5% Trimmed Mean
Median
Variance
Std. Dev iat ion
Minimum
Maximum
Range
Interquartile Range
Skewness
Kurt osis
Mean
95% Conf idence
Interv al f or Mean
5% Trimmed Mean
Median
Variance
Std. Dev iat ion
Minimum
Maximum
Range
Interquartile Range
Skewness
Kurt osis
Lower Bound
Upper Bound
Lower Bound
Upper Bound
Stat istic
14.4467
13.6744
Std. Error
.37758
15.2189
14.4796
14.4500
4.277
2.06810
10.00
18.10
8.10
2.18
-.322
.027
39.1533
38.0895
.427
.833
.52016
40.2172
39.2056
39.5000
8.117
2.84905
32.70
45.20
12.50
3.40
-.434
.301
.427
.833
11
Descriptives
PT setelah
menerima Heparin
APTT setelah
menerima Heparin
Mean
95% Conf idence
Interv al f or Mean
5% Trimmed Mean
Median
Variance
Std. Dev iat ion
Minimum
Maximum
Range
Interquartile Range
Skewness
Kurt osis
Mean
95% Conf idence
Interv al f or Mean
5% Trimmed Mean
Median
Variance
Std. Dev iat ion
Minimum
Maximum
Range
Interquartile Range
Skewness
Kurt osis
Lower Bound
Upper Bound
Lower Bound
Upper Bound
Stat istic
15.1400
14.3184
Std. Error
.40174
15.9616
15.0630
14.2000
4.842
2.20041
10.80
21.20
10.40
2.75
.768
.881
40.6167
39.4436
.427
.833
.57358
41.7898
40.5963
40.3500
9.870
3.14161
34.40
47.10
12.70
4.83
.223
-.564
.427
.833
12
Descriptives
PT sebelum
pasien keluar I CU
APTT sebelum
pasien keluar I CU
Mean
95% Conf idence
Interv al f or Mean
5% Trimmed Mean
Median
Variance
Std. Dev iat ion
Minimum
Maximum
Range
Interquart ile Range
Skewness
Kurt osis
Mean
95% Conf idence
Interv al f or Mean
5% Trimmed Mean
Median
Variance
Std. Dev iat ion
Minimum
Maximum
Range
Interquart ile Range
Skewness
Kurt osis
Lower Bound
Upper Bound
Lower Bound
Upper Bound
Stat istic
17.7267
16.6239
Std. Error
.53920
18.8294
17.7778
18.2000
8.722
2.95331
10.50
24.60
14.10
3.33
-.473
.843
44.4967
43.0826
.427
.833
.69140
45.9107
44.3667
44.0000
14.341
3.78695
38.70
53.00
14.30
4.95
.461
-.323
.427
.833
13
Tests of Normal ity
a
Kolmogorov -Smirnov
St at ist ic
df
Sig.
PT sebelum
menerima Heparin
APTT sebelum
menerima Heparin
PT set elah
menerima Heparin
APTT setelah
menerima Heparin
PT sebelum
pasien keluar ICU
APTT sebelum
pasien keluar ICU
St at ist ic
Shapiro-Wilk
df
Sig.
.119
30
.200*
.962
30
.352
.102
30
.200*
.974
30
.648
.199
30
.004
.939
30
.085
.089
30
.200*
.980
30
.822
.190
30
.007
.952
30
.190
.110
30
.200*
.965
30
.417
*. This is a lower bound of the true signif icance.
a. Lillief ors Signif icance Correction
Paired Samples Statistics
Mean
Pair
1
PT sebelum
menerima Heparin
PT setelah
menerima Heparin
N
Std. Dev iat ion
Std. Error
Mean
14.4467
30
2.06810
.37758
15.1400
30
2.20041
.40174
Paired Samples Test
Paired Dif f erences
Mean
Pair
1
PT sebelum menerima
Heparin - PT setelah
menerima Heparin
-.69333
St d. Dev iation
St d. Error
Mean
1.44650
.26409
95% Conf idence
Interv al of the
Dif f erence
Lower
Upper
-1.23347
-.15320
t
-2.625
df
Sig. (2-tailed)
29
Paired Samples Statistics
Mean
Pair
1
PT setelah
menerima Heparin
PT sebelum
pasien keluar ICU
N
Std. Dev iat ion
Std. Error
Mean
15.1400
30
2.20041
.40174
17.7267
30
2.95331
.53920
.014
14
Paired Samples Test
Paired Dif f erences
Mean
Pair
1
PT setelah menerima
Heparin - PT sebelum
pasien keluar ICU
Std. Dev iat ion
Std. Error
Mean
2.30856
.42148
-2.58667
95% Conf idence
Interv al of the
Dif f erence
Lower
Upper
-3.44870
-1.72463
t
df
Sig. (2-tailed)
-6.137
29
.000
Paired Samples Statistics
Mean
Pair
1
APTT sebelum
menerima Heparin
APTT setelah
menerima Heparin
N
Std. Dev iat ion
Std. Error
Mean
39.1533
30
2.84905
.52016
40.6167
30
3.14161
.57358
Paired Samples Test
Paired Dif f erences
Mean
Pair
1
APTT sebelum menerima
Heparin - APTT setelah
menerima Heparin
-1.46333
Std. Dev iat ion
Std. Error
Mean
2.55079
.46571
95% Conf idence
Interv al of the
Dif f erence
Lower
Upper
-2.41581
-.51085
t
df
-3.142
Sig. (2-tailed)
29
.004
Paired Samples Statistics
Mean
Pair
1
APTT setelah
menerima Heparin
APTT sebelum
pasien keluar ICU
N
Std. Dev iat ion
Std. Error
Mean
40.6167
30
3.14161
.57358
44.4967
30
3.78695
.69140
Paired Samples Test
Paired Dif f erences
Mean
Pair
1
APTT setelah menerima
Heparin - APTT sebelum
pasien keluar I CU
-3.88000
Std. Dev iat ion
Std. Error
Mean
2.78622
.50869
95% Conf idence
Interv al of the
Dif f erence
Lower
Upper
-4.92039
-2.83961
t
-7.627
df
Sig. (2-tailed)
29
.000
15
Dokumentasi Penelitian